EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Clinical Characteristics of Difficult‐To‐Treat Allergic Bronchopulmonary Aspergillosis and Its Prediction Score

Jun Tanaka, Tsuyoshi Oguma, Takashi Ishiguro, Hirokazu Taniguchi, Teruaki Nishiuma iD, Hiroki Tateno, Hisako Matsumoto, Naoki Koshimizu, Yutaka Ito, Kazuto Matsunaga, Hidekazu Matsushima, Yoshitaka Uchida iD und 8 weitere

Allergy · 2025

DOI: 10.1111/all.16559 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Allergy, 2025. Verfasst von Jun Tanaka und 19 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pulmonary Medicine, Department of Medicine, Tokai University School of Medicine, Isehara, Kanagawa, Japan. Hauptthemen laut MEDLINE: Aspergillosis, Allergic Bronchopulmonary, Antifungal Agents. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Japan Agency for Medical Research and Development.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Objective Administration of oral corticosteroids and/or azole antifungals for 4–6 months remains the standard treatment for allergic bronchopulmonary aspergillosis (ABPA). This study investigated the clinical characteristics of patients with difficult‐to‐treat ABPA who failed to achieve clinical remission within 6 months.

Methods

Among the participants of a nationwide survey conducted in Japan in 2020, treatment‐naïve patients with ABPA who satisfied Asano's criteria were enrolled in this study. Clinical remission was defined as stable disease without exacerbation for ≥ 6 months under minimal treatment (oral prednisolone: ≤ 5 mg/day and no antifungal medication). A risk prediction score for difficult‐to‐treat ABPA was developed and validated in an independent cohort comprising patients with ABPA from a prospective registration study in Japan.

Results

In total, 316 treatment‐naïve patients with ABPA were enrolled in the study. The median time to minimal treatment status was 4.8 months in the group receiving standard treatment. The clinical remission rate at 6 months after standard treatment was 51%. Age ≤ 50 years at onset of ABPA ( p = 0.04), serum A. fumigatus ‐specific IgE titer of ≥ 20 U A /mL ( p = 0.006), positive culture for Aspergillus spp. in the sputum/bronchial lavage fluid ( p = 0.05), and presence of high attenuation mucus (HAM; p = 0.10) were associated with difficult‐to‐treat ABPA. The number of positive indicators indicated the risk of failure of standard treatment to yield clinical remission within 6 months in the derivation ( n = 87, p < 0.001) and validation ( n = 64, p = 0.009) cohorts.

Conclusion

Multiple components, including age at onset, allergic sensitization, airway fungal burden, and HAM, were associated with difficult‐to‐treat ABPA.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Aspergillosis, Allergic BronchopulmonaryAntifungal AgentsHumansMaleFemaleMiddle AgedAdultAgedJapanTreatment OutcomePrognosisImmunoglobulin EProspective Studies

Stichwörter der Autor:innen

Aspergillus fumigatusallergic bronchopulmonary aspergillosisclinical remissionexacerbationimmunoglobulin E

Substanzen

Antifungal AgentsImmunoglobulin E

Autor:innen und Institutionen

  • Division of Pulmonary Medicine, Department of Medicine, Tokai University School of Medicine, Isehara, Kanagawa, Japan.
  • Department of Respiratory Medicine, Saitama Cardiovascular and Respiratory Center, Saitama, Japan.
  • Division of Respiratory Medicine, Toyama Prefectural Central Hospital, Toyama, Japan.
  • Department of Respiratory Medicine, Kakogawa Central City Hospital, Kakogawa, Japan.
  • Department of Pulmonary Medicine, Saitama City Hospital, Saitama, Japan.
  • Department of Respiratory Medicine and Allergology, Kindai University School of Medicine, Osaka, Japan.

ORCID-Profile: Teruaki Nishiuma, Yoshitaka Uchida

Förderung

  • Japan Agency for Medical Research and Development

Zitieren

APA

Tanaka, J., Oguma, T., Ishiguro, T., Taniguchi, H., Nishiuma, T., Tateno, H., Matsumoto, H., Koshimizu, N., Ito, Y., Matsunaga, K., Matsushima, H., Uchida, Y., Yokomura, K., Yasuba, H., Suzuki, J., Hattori, S., Okada, N., Tomomatsu, K., Asano, K., & ABPM Research Program (2025). Clinical Characteristics of Difficult‐To‐Treat Allergic Bronchopulmonary Aspergillosis and Its Prediction Score. Allergy. https://doi.org/10.1111/all.16559

Vancouver

Tanaka J, Oguma T, Ishiguro T, Taniguchi H, Nishiuma T, Tateno H, et al. Clinical Characteristics of Difficult‐To‐Treat Allergic Bronchopulmonary Aspergillosis and Its Prediction Score. Allergy. 2025. doi:10.1111/all.16559

BibTeX
@article{Tanaka2025,
  author = {Tanaka, Jun and Oguma, Tsuyoshi and Ishiguro, Takashi and Taniguchi, Hirokazu and Nishiuma, Teruaki and Tateno, Hiroki and Matsumoto, Hisako and Koshimizu, Naoki and Ito, Yutaka and Matsunaga, Kazuto and Matsushima, Hidekazu and Uchida, Yoshitaka and Yokomura, Koshi and Yasuba, Hirotaka and Suzuki, Junko and Hattori, Shigeaki and Okada, Naoki and Tomomatsu, Katsuyoshi and Asano, Koichiro and ABPM Research Program, ABPM Research Program},
  title = {Clinical Characteristics of Difficult‐To‐Treat Allergic Bronchopulmonary Aspergillosis and Its Prediction Score},
  journal = {Allergy},
  year = {2025},
  doi = {10.1111/all.16559}
}
Kostenlos starten →